ReviewHuman vaccines & immunotherapeutics2013
DNA vaccines: a simple DNA sensing matter?
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.Nature biotechnology · 2026Article
- Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity.Human vaccines & immunotherapeutics · 2025Article
- New insights for the development of efficient DNA vaccines.Microbial biotechnology · 2024Review
- Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses.Viruses · 2024Review
- 704/DNA vaccines leverage cytoplasmic DNA stimulation to promote anti-HIV neutralizing antibody production in mice and strong immune response against alpha-fetoprotein in non-human primates.Molecular therapy. Nucleic acids · 2023Article
- Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19).Archives of microbiology · 2023Review
- In vitro and in vivo correlation of skin and cellular responses to nucleic acid delivery.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- DNA vaccines against COVID-19: Perspectives and challenges.Life sciences · 2021Review
- Revisiting the Development of Vaccines Against PathogenicFrontiers in immunology · 2021Review
- Nucleic Acid-Based Approaches for Tumor Therapy.Cells · 2020Review
- Immunotherapeutic Activities of a DNA Plasmid Carrying the Mycobacterial hsp65 Gene (DNAhsp65).Frontiers in medical technology · 2020Review
- Review
- Review
- DNA Vaccines-How Far From Clinical Use?International journal of molecular sciences · 2018Review
- Effective usage of cationic derivatives of polyprenols as carriers of DNA vaccines against influenza virus.Virology journal · 2017Article
- Article
- DNA-launched live-attenuated vaccines for biodefense applications.Expert review of vaccines · 2016Review
- Novel antigen delivery systems.World journal of virology · 2015Article
- Immunogenicity of infectious pathogens and vaccine antigens.BMC immunology · 2015Review
- Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the introduction of DNA vaccines two decades ago, this attractive strategy has been hampered by its low immunogenicity in humans. Studies conducted to improve the immunogenicity of DNA vaccines have shown that understanding the mechanism of action of DNA vaccines might be the key to successfully improving their immunogenicity. Our current understanding is that DNA vaccines induce innate and adaptive immune responses in two ways: (1) encoded protein (or polypeptide) antigen(s) by the DNA plasmid can be expressed in stromal cells (i.e., muscle cells) as well as DCs, where these antigens are processed and presented to naïve CD4 or CD8 T cells either by direct or cross presentation, respectively; and (2) the transfected DNA plasmid itself may bind to an un-identified cytosolic DNA sensor and activate the TBK1-STING pathway and the production of type I interferons (IFNs) which function as an adjuvant. Recent studies investigating double-stranded cytosolic DNA sensor(s) have highlighted new mechanisms in which cytosolic DNA may release secondary metabolites, which are in turn recognized by a novel DNA sensing machinery. Here, we discuss these new metabolites and the possibilities of translating this knowledge into improved immunogenicity for DNA vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.